Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says

Executive Summary

Uncontrolled studies published in peer-reviewed journals should be acceptable as promotional information if disseminated with an FDA disclaimer, the Washington Legal Foundation said during FDA's public hearing on direct-to-consumer advertising Nov. 1-2

You may also be interested in...



PhRMA DTC Guideline Compliance Could Avert Plaintiff, DoJ Backlash – Troy

Responding to warning and untitled letters from FDA's Division of Drug Marketing, Advertising & Communications could help to shield firms in the event of product liability suits, according to former FDA Chief Counsel Daniel Troy

FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information

An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information

WLF Questions Ad Division Allegations; “DDMAC Watch” Starts With Strattera

Direct-to-consumer advertising does not endanger the public health because access to prescription drugs is controlled by physicians, not the public, the Washington Legal Foundation's new advertising regulation watchdog group suggests

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel